A total of 917 adult patients in Trials 1 and 2 (16-week trials) and 421 adult patients in Trial 3 (52-week trial) with moderate-to-severe atopic dermatitis not adequately controlled with topical treatments were randomized to DUPIXENT 300 Q2W or placebo. For all patients in Trial 3, lesions were treated with concomitant TCS.
All studies initiated with two 300 mg DUPIXENT or placebo subcutaneous injections at Week 0
Disease severity was defined by an IGA score ≥3 in the overall assessment of atopic dermatitis lesions on a severity scale of 0 to 4, and EASI score ≥16 on a scale of 0 to 72, and a minimum body surface area involvement of ≥10%.1
QW dosing was also studied in a randomized treatment arm but no additional benefit was seen over Q2W dosing.
QW, once every week; Q2W, once every 2 weeks.